CHOLANGIOCARCINOMA

This early-phase study tested the safety of a new drug, INCB062079, in 25 people with advanced liver cancer or other solid tumors. The goal was to find a safe dose and see how well patients tolerated the treatment. The study was terminated early, so results are limited.

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique mutations in their cancer. It was designed for people with advanced solid tumors like lung, pancreatic, or ovarian cancer who had not responded to s…

This early-stage study tested an experimental virus therapy called VAXINIA (CF33-hNIS) in 66 adults with advanced solid tumors that had spread. The virus was given either directly into tumors or through a vein, alone or with the immunotherapy drug pembrolizumab. The main goal was…

This study tested a new drug called felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors (like ovarian, breast, lung, and others). The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This study looked at genetic mutations in tumors from 565 people with cancers of the liver, bile ducts, gallbladder, pancreas, esophagus, or stomach. The goal was to see how often these mutations occur and whether they can help doctors choose more personalized treatments. The stu…

This study aimed to see if blood-based DNA tests (liquid biopsies) could help doctors make better treatment decisions for people with advanced colorectal, pancreatic, or bile duct cancer. Researchers planned to enroll about 16 participants to check if these tests change how patie…

This study aimed to create a registry of tissue and blood samples from 1,000 people undergoing surgery or biopsy for liver or bile duct tumors. The samples were stored for future research to better understand these cancers and develop new treatments. The study was terminated earl…